EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Xenon Pharmaceuticals's enterprise value is $2,472.34 Mil.
Xenon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-210.51 Mil. Therefore, Xenon Pharmaceuticals's EV-to-EBITDA for today is -11.74.
The historical rank and industry rank for Xenon Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
XENE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -38 Med: -7.51 Max: 68.08
Current: -11.74
During the past 13 years, the highest EV-to-EBITDA of Xenon Pharmaceuticals was 68.08. The lowest was -38.00. And the median was -7.51.
XENE's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs XENE: -11.74
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Xenon Pharmaceuticals's stock price is $39.50.
Xenon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.720. Therefore, Xenon Pharmaceuticals's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Xenon Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Xenon Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xenon Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Xenon Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenon Pharmaceuticals EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's EV-to-EBITDA falls into.
Xenon Pharmaceuticals EV-to-EBITDA Calculation
Xenon Pharmaceuticals's EV-to-EBITDA for today is calculated as:
Xenon Pharmaceuticals's current Enterprise Value is $2,472.34 Mil.
Xenon Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-210.51 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Xenon Pharmaceuticals's PE Ratio for today is calculated as:
Xenon Pharmaceuticals's share price for today is $39.50.
Xenon Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Xenon Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XENE has been successfully added to your 